The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence

Catheterization and Cardiovascular Interventions

Volumn 86, Issue 4, 2015, Pages 664-677

  Rizik, David G ^a   Hermiller, James B ^b   Kereiakes, Dean J ^c,d  

^a HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^b St Vincent s Heart Center of Indiana   (United States)

^c CHRIST HOSPITAL   (United States)

^d The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

ABSORB BVS; bioresorbable vascular scaffold; fourth revolution; safety; stent; vascular reparative therapy

Indexed keywords

EVEROLIMUS; UMIROLIMUS; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BIOLIMUS ELUTING CORONARY STENT; BIORESORBABLE VASCULAR STENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CORONARY FLOW RESERVE; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; EQUIPMENT DESIGN; EVEROLIMUS ELUTING CORONARY STENT; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MALAPPOSITION; MEDICAL DEVICE COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); RESTENOSIS; SAPHENOUS VEIN GRAFT; SCAFFOLD DISCONTINUITY; SCAFFOLD DISRUPTION; STENT THROMBOSIS; BIODEGRADABLE IMPLANT; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; MALE; MORTALITY; PROCEDURES; PROSTHESIS DESIGN; RADIOGRAPHY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTOR; TISSUE SCAFFOLD; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTHESIS DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84941949068     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26172     Document Type: Article

References (68)

1. Goldstein JA., Bioresorbable coronary devices: Advances illuminated by imaging. J Am Coll Cardiol Img 2014; 7: 1149-1150.
2. Garcia-Garcia HM, Serruys PW, Campos CM, et al., Assessing bioresorbable coronary devices: Methods and parameters. J Am Coll Cardiol Img 2014; 7: 1130-1148.
3. Waksman R, Prati F, Bruining N, et al., Serial observation of drug-eluting absorbable metal scaffold: Multi-imaging modality assessment. Circ Cardiovasc Interv 2013; 6: 644-653.
4. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de BB, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.
5. Serruys PW, Onuma Y, Ormiston JA, de BB, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM., Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. Circulation 2010; 122: 2301-2312.
6. Onuma Y, Serruys PW, Gomez J, de BB, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA., Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011; 78: 3-12.
7. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43-54.
8. Oberhauser JP, Hossainy S, Rapoza RJ., Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention 2009; 5 (Suppl F): F15-F22.
9. Chevalier B., First report of the four year clinical results of the ABSORB trial evaluating the Absorb everolimus eluting bioresorbable vascular scaffold in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol 2013; 62 (18 Suppl B): B11 TCT-32.
10. Abizaid A, Costa JR Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong WF, Sudhir K, Serruys PW., The ABSORB EXTEND study: Preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2014; 10: 1396-1401.
11. Abizaid A., ABSORB Update: The Extend Real World Registry. Transcatheter Cardiovascular Therapeutics (TCT) Congress 2014. 2014. Available at: http://www.tctmd.com/show.aspx?id=126638. Accessed January 30, 2015.
12. Smits P., ABSORB Extend: An Interim Report on the 36-Month Clinical Outcomes From the First 250 Patients Enrolled. Transcatheter Cardiovascular Therapeutics (TCT) Congress 2014. 2014. Available at: URL: http://www.tctmd.com/show.aspx?id=125477. Accessed January 30, 2015.
13. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S., Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015; 65: 791-801.
14. Simonton C., Absorb™ Fully Bioresorbable Vascular Scaffold (BVS): Emerging Real-World Clinical Data Optimal Implant Techniques. Abbott CMO News Report. 2014. Available at: http://www.six-degrees.com/pdf/TEST.pdf. Accessed January 30, 2015.
15. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de BB, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA., Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9: 1271-1284.
16. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D., A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
17. Gould KL, Lipscomb K, Hamilton GW., Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974; 33: 87-94.
18. Berne RM., The role of adenosine in the regulation of coronary blood flow. Circ Res 1980; 47: 807-813.
19. Palmer RM, Ferrige AG, Moncada S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
20. Ormiston J, Webster M, Armstrong G., First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-l-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69: 128-131.
21. Furchgott RF, Zawadzki JV., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
22. Murthy VL, Naya M, Foster CR, et al., Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011; 124: 2215-2224.
23. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease: role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol 2013; 62: 1639-1653.
24. Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW., Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB cohort A trial. J Am Coll Cardiol Intv 2013; 6: 999-1009.
25. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de BB, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.
26. Wykrzykowska JJ, Onuma Y, Serruys PW., Vascular restoration therapy: The fourth revolution in interventional cardiology and the ultimate "rosy" prophecy. EuroIntervention 2009; 5 (Suppl F): F7-F8.
27. Bourantas CV, Serruys PW, Nakatani S, Zhang YJ, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns RJ, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia HM., Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: A concept based on serial optical coherence tomography data. EuroIntervention 2014; pii: 20140223-01. doi: 10.4244/EIJY14M10-06. [Epub ahead of print].
28. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW., Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque? Atherosclerosis 2012; 221: 106-112.
29. Morris PD, van de Vosse FN, Lawford PV, et al., "Virtual" (computed) fractional flow reserve: Current challenges and limitations. JACC Cardiovasc Interv 2015; 8: 1009-1017.
30. Neglia D, Rovai D, Caselli C, et al., Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imag 2015; 8: pii: e002179.
31. Hosogi S, Shimizu H, Tanaka M., Multiple inter-strut hollow, a unique finding of optical coherence tomography after sirolimus eluting stent implantation: The prevalence and clinical characteristics. Circulation 2009; 120: S1001.
32. Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, Achenbach S, Pan AM, Nef H, Lesiak M, Di MC, Colombo A, Naber CK, Caramanno G, Capranzano P, Brugaletta S, Geraci S, Araszkiewicz A, Mattesini A, Pyxaras SA, Rzeszutko L, Depukat R, Diletti R, Boone E, Capodanno D, et al., Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective. EuroIntervention 2015; 11: 45-52.
33. Capodanno D, Gori T, Nef H, et al., Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10: 1144-1153.
34. Grube E, Chevalier B, Smits P, et al., The SPIRIT V Study: A clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. J Am Coll Cardiol Intv 2011; 4: 168-175.
35. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Munzel T, Lee CH, Cequier A, Valdes M, Widimsky P, Serruys PW, Sabate M., Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-Year results of a propensity score matching comparison: The BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). J Am Coll Cardiol Intv 2015; 8 (1 Pt B): 189-197.
36. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW., Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: An interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. J Am Coll Cardiol Intv 2013; 6: 247-257.
37. Byrne RA, Kastrati A., Bioresorbable drug-eluting stents: An immature technology in need of mature application. J Am Coll Cardiol Intv 2015; 8 (1 Pt B): 198-200.
38. Goldstein JA, Maini B, Dixon SR., Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction. Circ Cardiovasc Interv 2011; 4: 429-437.
39. Everaert B, Felix C, Koolen J, den HP, Henriques J, Wykrzykowska J, van der SR, de SB, Hofma S, Diletti R, Van MN, Regar E, Smits P, van Geuns RJ., Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: A recommendation from experienced users: A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J 2015; 23: 161-165.
40. Cortese B, Valgimigli M., Current know how on the Absorb BVS technology: An experts' survey. Int J Cardiol 2015; 180: 203-205.
41. Rzeszutko L, Depukat R, Dudek D., Biodegradable vascular scaffold ABSORB-scientific evidence and methods of implantation. Postepy Kardiol Interwencyjnej 2013; 9: 22-30.
42. Lesiak M, Araszkiewicz A., "Leaving nothing behind": Is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease? Postepy Kardiol Interwencyjnej 2014; 10: 283-288.
43. Witzenbichler B, Maehara A, Weisz G, et al., Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: The ADAPT-DES study. Circulation 2014; 129: 463-470.
44. Wang L, Mintz GS, Witzenbichler B, Metzger DC, et al., Differences in Underlying Culprit Lesion Morphology Between Men and Women: An IVUS Analysis From the ADAPT-DES Study. JACC Cardiovasc Imag 2015; pii: S1936-878X(15)00260-0. doi: 10.1016/j.jcmg.2015.02.019. [Epub ahead of print].
45. Wiebe J, Nef HM, Hamm CW., Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014; 64: 2541-2551.
46. Eeckhout E., ABSORB FIRST: An interim report on baseline characteristics and acute performance on the first 1,200 patients from a prospective, multi-center, global registry. J Am Coll Cardiol 2014; 64 (11 Suppl B): B179 TCT-613.
47. Naber C., ABSORB FIRST: An interim report on baseline characteristics, acute performance on the first 1200 patients from a prospective, multi-center, global registry. Transcatheter Cardiovascular Therapeutics (TCT) Congress 2014. 2014. Available at: http://www.tctmd.com/show.aspx?id=126640. Accessed January 30, 2015.
48. Seth A., ABSORB FIRST: An interim report on baseline characteristics, acute performance from the first 500+ patients from a prospective, multicentre, global registry. EuroIntervention 2013;Euro14A-OP185.
49. Wohrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, Brachmann J, Ingwersen M, Drabik A, Markovic S, Mathey DG., Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2015; 11: 149-156.
50. Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, Baan J Jr, Vis MM, Arkenbout EK, Tijssen JG, de Winter RJ, Wykrzykowska JJ., Initial experience and clinical evaluation of the ABSORB bioresorbable vascular scaffold (BVS) in real-world practice: The AMC single centre real world PCI registry. EuroIntervention 2015; 10: 1160-1168.
51. Dudek D, Rzeszutko L, Zasada W, Depukat R, Siudak Z, Ochala A, Wojakowski W, Przewlocki T, Zmudka K, Kochman J, Lekston A, Gasior M., Bioresorbable vascular scaffolds in patients with acute coronary syndromes: The POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-677.
52. Mojoli M, Tarantini G, Varricchio A, et al., Clinical outcomes of overlapping ABSORB BVS for the treatment of long coronary lesions: Data from the Italian RAI multicenter registry. JACC Cardiovasc Interv 2015; 82 (Suppl 1): S43-S44.
53. Ielasi A, Cortese B, Varricchio A, Tespili M, Sesana M, Pisano F, Loi B, Granata F, Moscarella E, Silva Orrego P, La Vecchia L, Steffenino G., Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre "Registro ABSORB Italiano" (RAI registry). EuroIntervention 2015; 11: 157-162.
54. Im E, Kim B-K, Ko YG, et al., Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation. Circ Cardiovasc Interv. 2014; 7: 88-96.
55. Guo N, Maehara A, Mintz GS, et al., Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: An intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation 2010; 122: 1077-1084.
56. Goldstein JA, Demetriou D, Grines CL., Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922.
57. Bourantas CV, Garcia-Garcia HM, Farooq V, et al., Clinical and angiographic characteristics of patients likely to have vulnerable plaques: Analysis from the PROSPECT study. JACC Cardiovasc Imag 2013; 6: 1263-1272.
58. Wald DS, Morris JK, Wald NJ., Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369: 1115-1123.
59. Iqbal J, Onuma Y, van Geuns RJ, Chevalier B, Muramatsu T, Zhang Y-J, Veldhof S, Smits PC, Whitbourn RJ, Bartorelli AL, Stone GW, Abizaid A, Serruys PW., Diabetic patients treated with bioresorbable vascular scaffolds show good clinical outcomes at two-year follow-up: A pooled analysis from the ABSORB and SPIRIT trials. J Am Coll Cardiol 2014; 64 (11 Suppl B): B72.
60. Shah A, Chan W, Overgaard C, Ing D, Dzavik V., Safety and feasibility of everolimus-eluting bioresorbable vascular scaffold in the treatment of coronary bifurcation lesions. JACC Cardiovasc Interv 2015; 82 (Suppl 1): S18.
61. Seth A, Sengottuvelu G, Ravisekar V., Salvage of side branch by provisional "TAP technique" using ABSORB bioresorbable vascular scaffolds for bifurcation lesions: First case reports with technical considerations. Catheter Cardiovasc Interv 2014; 84: 55-61.
62. Cortese B, Orrego PS, Sebik R, Sesana M, Pisano F, Zavalloni D, Steffenino G, Seregni R., Biovascular scaffolding of distal left main trunk: Experience and follow up from the multicenter prospective RAI registry (Registro Italiano Absorb). Int J Cardiol 2014; 177: 497-499.
63. Sato K, Latib A, Panoulas VF, Naganuma T, Miyazaki T, Colombo A., A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting. JACC Cardiovasc Interv 2014; 7: e103-e104.
64. Ojeda S, Pan M, Romero M, Suarez de Lezo J, Mazuelos F, Segura J, Espejo S, Morenate C, Blanco M, Martin P, Medina A, Suarez de Lezo J., Outcomes and computed tomography scan follow-up of bioresorbable vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion. Am J Cardiol 2015; 115: 1487-1493.
65. Vaquerizo B, Barros A, Pujadas S, Bajo E, Estrada D, Miranda-Guardiola F, Rigla J, Jimenez M, Cinca J, Serra A., Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study. EuroIntervention 2014; pii: 20140601-04.
66. Basavarajaiah S, Naganuma T, Latib A, Colombo A., Can bioabsorbable scaffolds be used in calcified lesions? Catheter Cardiovasc Interv 2014; 84: 48-52.
67. Alfonso F, Nuccio J, Cuevas C, Cardenas A, Gonzalo N, Jimenez-Quevedo P., Treatment of coronary in-stent restenosis with bioabsorbable vascular scaffolds. J Am Coll Cardiol 2014; 63 (25 Pt A): 2875.
68. Ong PJ, Jafary FH, Ho HH., "First-in-man" use of bioresorbable vascular scaffold in saphenous vein graft. EuroIntervention 2013; 9: 165.